News Articles on Wyeth Pharmaceuticals

FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia

Indication Offers New Option for Adult Patients Suffering From Community-Acquired Bacterial Pneumonia

COLLEGEVILLE, Pa.,
http://www.bioportfolio.com/news/FDA_Approves_New_Indication_for_Wyeth%26apos%3Bs.html - Tuesday March 24 2009

CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture

COLLEGEVILLE, Pa., Feb. 19 /PRNewswire-FirstCall/ -- The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the Eur
http://www.bioportfolio.com/news/CONBRIZA_Receives_Positive_CHMP_Opinion_for_the.html - Thursday February 19 2009

Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines

COLLEGEVILLE, Pa., & HOERSHOLM, Denmark, Jan. 12 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Santaris
http://www.bioportfolio.com/news/Wyeth_Pharmaceuticals_and_Santaris_Pharma.html - Monday January 12 2009

Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children

COLLEGEVILLE, Pa., Dec. 3 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has submitt
http://www.bioportfolio.com/news/Wyeth_Submits_European_Marketing_Authorization.html - Wednesday December 3 2008

Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two

- Data presented at the joint annual meeting of ICAAC and IDSA

- Results suggest candidate vaccine may be as effective
http://www.bioportfolio.com/news/Phase_3_Data_Indicate_Investigational_13-valent.html - Monday October 27 2008

New Recombinant XYNTHA Now Available for Patients with Hemophilia A

COLLEGEVILLE, Pa., Sept. 8 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that product shipments have
http://www.bioportfolio.com/news/New_Recombinant_XYNTHA_Now_Available_for_Patients.html - Monday September 8 2008

New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer

COLLEGEVILLE, Pa., May 31 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced results of two new
http://www.bioportfolio.com/news/New_Analyses_Presented_at_ASCO_Reaffirmed.html - Saturday May 31 2008